Ensaio em fase de recrutamento = ; Ensaio a decorrer = ; Ensaio concluído = ; Financiado por um membro do IRDiRC = ; Estudo envolvendo membros das ERN em pelo menos dois Estados-Membros =

Ensaio (s) clínico (s) nacional (is)

PAISES BAIXOS

Zuid-Holland
LEIDEN

Exploratory study on the local dystrophin production restoring effect and safety and tolerability of a single intramuscular dose of antisense oligoribonucleotide PRO051 in Duchenne muscular dystrophy patients.

LUMC - Leids Universitair Medisch Centrum

Polikliniek Neurologie

Mais detalhes

PAISES BAIXOS

Zuid-Holland
LEIDEN

A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Doses of PRO044 in Patients With Duchenne Muscular Dystrophy

LUMC - Leids Universitair Medisch Centrum

Polikliniek Neurologie

Mais detalhes

PAISES BAIXOS

Zuid-Holland
LEIDEN

DMD114044: A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy - NL (Completed)

LUMC - Leids Universitair Medisch Centrum

Polikliniek Neurologie

Mais detalhes

PAISES BAIXOS

Zuid-Holland
LEIDEN

An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (Phase III) (Completed)

LUMC - Leids Universitair Medisch Centrum

Polikliniek Neurologie

Mais detalhes

PAISES BAIXOS

Zuid-Holland
LEIDEN

A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD) - NL

LUMC - Leids Universitair Medisch Centrum

Polikliniek Neurologie

Mais detalhes